Active Surveillance for Localized Prostate Cancer

1. Cancer Overdiagnosis and Overtreatment
Laurence Klotz

2. Can We Screen and Still Reduce Overdiagnosis?
Peter Ka-Fung Chiu, Monique J. Roobol

3. The Role of Fear in Overdiagnosis and Overtreatment
Iona Heath

4. Ethical and Legal Considerations in Active Surveillance for Prostate Cancer
Lionne D. F. Venderbos

5. Gleason 6 Tumors Should Still Be Labeled as Cancer
Angelo M. Marzo, Jonathan I. Epstein

6. Risk-Based Selection for Active Surveillance
Jan F. M. Verbeek, Monique J. Roobol, Ewout W. Steyerberg

7. Surveillance at the Margins: Management of High-Volume Gleason 6, PSA > 10, or Gleason 3 + 4
Laurence Klotz

8. How Should Patients on Active Surveillance Be Followed?
Frank-Jan H. Drost, Monique J. Roobol, Leonard P. Bokhorst

9. Triggers for Intervention
Tuomas Mirtti, Hanna Vasarainen, Antti Rannikko

10. MR Imaging in Prostate Tumor Volume Assessment: How Accurate?
Ivo G. Schoots, Theo H. Kwast

11. Can MRI Replace Biopsy in Men on Surveillance?
Francesco Giganti, Vasilis Stavrinides, Caroline M. Moore

12. Tissue-Based Markers for Risk Prediction
Chad A. Reichard, Eric A. Klein

13. International AS Registry: The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative
Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen, Liying Zhang, Rachelle Kirk-Burnnand, Sam Gledhill, Mark Buzza

14. Better-Informed Decision-Making to Optimize Patient Selection
Lara Bellardita, Paola Dordoni, Letizia Luca, Julia Paola Menichetti Delor, Riccardo Valdagni

15. How Does QoL Compare Between Surveillance and Active Treatment?
Lionne D. F. Venderbos, Stephanie D. Brandhof, Ida J. Korfage

16. The Potential Benefits of Diet and Physical Activity Among Active Surveillance Patients with Low-Burden Prostate Cancer
Stacey A. Kenfield, David Tat, June M. Chan

17. Is There a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin
Roy Mano, David Margel

18. The Update of Active Surveillance Around the World: Utilization and Outcomes
Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor, Stacy Loeb

19. Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies
Juan Gómez Rivas, Mark Emberton

20. The Economics of Active Surveillance for Prostate Cancer
Robert B. Lurvey, Marc A. Dall’Era

21. Research Questions in Active Surveillance
Laurence Klotz

Nyckelord: Medicine & Public Health, Urology, Oncology, Imaging / Radiology, Geriatrics/Gerontology